Verastem Inc (VSTM) - News Archive

In the rapidly advancing realm of oncology, where the focus on precision medicine is paramount, Verastem Oncology has made significant strides in the treatment of cancers driven by the RAS/MAPK pathway. The biopharmaceu...

: The article details the primary results from the Phase 2 RAMP 201 clinical trial of avutometinib in combination with defactinib, as recently published by Verastem Oncology in the Journal of Clinical Oncology. The rese...

In a significant milestone for oncology, Verastem Oncology has announced that the U.S. Food and Drug Administration (FDA) has granted approval for AVMAPKI FAKZYNJA, a combination therapy comprising vutometinib capsules...

Advancing Cancer Treatments: Verastem Oncology s Notable 2024 Achievements Verastem Oncology, a biopharmaceutical company focused on developing innovative cancer treatments, has recently unveiled its financial results f...

Verastem Oncology s Groundbreaking Advancements in Ovarian Cancer Treatment: FDA Accepts NDA for Avutometinib and Defactinib In a significant stride towards enhancing therapeutic options for patients suffering from recu...

The landscape of cancer treatment is continually evolving, driven by innovative research and breakthroughs in drug development. Among the forefront companies leading this charge is Verastem Oncology, which has recently...

Unveiling a New Chapter in Cancer Treatment: Verastem Oncology s Breakthrough Therapy for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer The world of oncology is complex, fraught with battles against some of the...

Beating the Odds: Verastem Oncology s Bold Leap Towards a Groundbreaking Ovarian Cancer Treatment In an era where medical breakthroughs continually reshape the landscape of oncology, one small biopharmaceutical company...

In a significant milestone for cancer treatment, Verastem Oncology (Nasdaq: VSTM) has announced the completion of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a groundbreakin...

: The biopharmaceutical landscape is witnessing significant advancements as precision medicine continues to shape cancer treatment paradigms. Verastem Oncology, a pioneering entity in this realm, recently announced the...

Verastem Oncology Unveils Promising Results from RAMP 201 Trial for Ovarian Cancer Treatment at IGCS 2024 Annual MeetingBOSTON Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to developing innova...

Verastem Oncology, a committed biopharmaceutical entity focused on advancing innovative cancer therapies, has recently made significant strides in the ongoing fight against cancer. The company has announced upcoming det...

Verastem Oncology (Nasdaq: VSTM), a dedicated biopharmaceutical company focused on developing innovative therapies for cancer patients, has recently released its financial results for the second quarter of 2024, accompa...

Verastem Oncology s Recent Breakthroughs Propelling Innovation in Pancreatic Cancer Treatment Boston - In a significant stride toward improving treatment options for pancreatic cancer, Verastem Oncology (Nasdaq: VSTM),...

In a significant development for pancreatic cancer treatment, Verastem Oncology announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy consist...

Verastem Inc (NASDAQ: VSTM) has witnessed a surge in its stock price recently, driven by a series of positive developments. From a boost in price targets by leading research firms to the initiation of groundbreaking cli...

Verastem Inc s Performance in Comparison to the Market:Year to date, Verastem Inc shares have failed to mirror the performance of the broader market, with a lackluster increase of just 18.79%. This raises concerns about...

Verastem Inc (NASDAQ: VSTM) is a leading biopharmaceutical company dedicated to advancing innovative medicines for patients battling cancer. The company has recently made significant announcements and achieved notable m...

BOSTON July 1, 2024 Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company dedicated to advancing new medicines for patients with cancer, has announced pivotal achievements that underscore its commitment to cance...

Verastem Inc, a pharmaceutical company listed on NASDAQ under the ticker symbol VSTM, has been facing challenges in the market. This article aims to analyze the company s recent performance, investor claims, net loss, a...